NCT02334423View on ClinicalTrials.gov

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001

PHASE3CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Glabellar Frown Lines
Interventions
BIOLOGICAL

Botulinum toxin, Type A

Botulinum toxin, Type A

OTHER

0.9% sterile, unpreserved saline

Placebo

Trial Locations (1)

33431

Steven Fagien, MD, Boca Raton

Sponsors

Lead Sponsor

Evolus, Inc.

Collaborators (1)

PPD Development, LP
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

lead

Evolus, Inc.

INDUSTRY